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Abstract
OBJECTIVE: Myelin oligodendrocyte glycoprotein (MOG) is one of the major autoantigens in
multiple  sclerosis  (MS),  therefore selective depletion of  autoreactive lymphocytes exposing
MOG-specific B cell receptors (BCRs) would be beneficial in terms of MS treatment.RESULTS:
Using  E.  coli  we  generated  an  efficient  protocol  for  the  purification  of  the  recombinant
immunotoxin DT-MOG composed of the extracellular Ig-like domain of MOG fused in frame with
the catalytic and translocation subunits of diphtheria toxin (DT, Corynebacterium diphtheriae)
under native conditions with a final yield of 1.5 mg per liter of culture medium. Recombinant DT-
MOG was recognized in vitro by MOG-reactive antibodies and has catalytic activity comparable
with  wild-type  DT.CONCLUSION:  Enhanced  pharmacokinetics  (mean  residence  time  in  the
bloodstream of 61 min) and minimized diminished nonspecific toxicity (LD50 = 1.76 mg/kg) of
the DT-MOG makes it a potential candidate for the immunotherapy of MS.
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